Manufacture

How much do the public really know about pharma R&D?

Some drug shortage prevention plans fail, while others succeed. Why? ISPE helps companies find the answer

A US government study reports progress – but also highlights shortfalls

Regulators and manufacturers are readying for the opening of the US market, but legal wrangles continue to block the way.

Dr Paul Kippax is looking at how recent innovations are enhancing the value and informational productivity of some of our analytical techniques.

Researchers examine the application and usefulness of nanoparticle tracking analysis and dynamic light scattering techniques in the characterization of liposomes used as drug delivery vehicles.

Progress is too often hampered by our inability to gather the information needed to make advances.

Analytical QbD (AQbD) promises to extend the rigor and benefits of QbD into the area of analytical method development.

Sitting Down With... Dirk Sauer, Novartis’ Global Head, Development Franchise Ophthalmics.

Will bacteriophages be the savior of the human race in the post-antibiotic era or is it just pie in the sky?